**Core Concept**
Varenicline is a partial agonist of the alpha4beta2 nicotinic acetylcholine receptor, used in smoking cessation therapy to reduce cravings and the pleasurable effects of smoking.

**Why the Correct Answer is Right**
Varenicline acts by binding to the alpha4beta2 nicotinic receptors in the brain, which are responsible for the rewarding and addictive effects of nicotine. By occupying these receptors, varenicline reduces the release of dopamine, thereby decreasing the pleasurable sensations associated with smoking. This leads to a reduction in cravings and the desire to smoke.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because varenicline is not primarily used for the treatment of anxiety disorders.
**Option B:** This option is incorrect because varenicline is not a first-line treatment for attention deficit hyperactivity disorder (ADHD).
**Option C:** This option is incorrect because varenicline is not used for the management of opioid addiction.

**Clinical Pearl / High-Yield Fact**
Varenicline's mechanism of action is unique among smoking cessation therapies, as it targets the nicotinic receptors directly involved in nicotine addiction. This highlights the importance of understanding the pharmacology of addictions and the role of nicotinic receptors in the brain.

**Correct Answer: C. Smoking cessation**